Cystic Fibrosis Foundation

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA and CASPER, as well as analytical tools such as Lonestar and ATLAS, catering to applications like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced sensitivity and selectivity. Owlstone Medical aims to become a global leader in non-invasive diagnostics, with a focus on early disease detection and a pipeline of medical applications, including colon and lung cancer screening.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Clarametyx Biosciences, Inc. is a biotechnology company founded in 2020 and headquartered in Columbus, Ohio. The company focuses on developing targeted and immune-enabling biologic therapies that address persistent infections associated with biofilms, which are protective layers that shield bacteria and complicate treatment. Clarametyx has created a novel technology platform that allows for the targeting of these biofilms, thereby enhancing immune response and facilitating antibiotic intervention. One of its key products in development is CMTX-001, a humanized monoclonal antibody currently in the late preclinical stage, aimed at treating hospital-acquired pneumonia. Clarametyx Biosciences is dedicated to combating life-threatening infections and reducing antibiotic resistance through its innovative therapeutic solutions.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Arcturus Therapeutics is an RNA medicines company based in San Diego, California, founded in 2013. It specializes in the discovery and development of novel RNA therapeutics aimed at treating rare diseases, particularly in the areas of liver and respiratory care. The company leverages its proprietary Self-Transcribing and Replicating RNA (STARR) technology and Unlocked Nucleic Acid (UNA) chemistry to create RNA drug substances and nanoparticle-formulated products. Arcturus's pipeline includes several preclinical and clinical programs, such as LUNAR-OTC for ornithine transcarbamylase deficiency, LUNAR-CF for cystic fibrosis, and LUNAR-COV19, a vaccine candidate targeting the Coronavirus outbreak. The company holds a robust patent portfolio, encompassing 182 patents and applications globally, enabling it to target any gene in the human genome. Furthermore, Arcturus has established collaborations with various pharmaceutical partners to advance its therapeutic candidates across multiple disease indications.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite integrates advanced high-throughput experimental and computational techniques to create tailored delivery vehicles capable of transporting a diverse array of genetic materials with specific targeting capabilities. This innovative approach aims to assist scientists in functional chemistry by providing therapeutically relevant solutions for gene delivery, enhancing the potential for various medical applications and indications.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Gensaic is a company focused on redefining gene therapy through its innovative bacteriophage-based platform. This platform is designed to treat human diseases by addressing significant limitations in existing gene therapy methods. Gensaic's technology allows for durable therapeutic effects through repeat administration, enabling targeted delivery to specific tissues. Additionally, the platform supports scalable manufacturing processes, enhancing the potential for widespread application in genomic medicine. Through its advancements, Gensaic aims to create impactful solutions in the treatment of various human conditions.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Carmine Therapeutics, established in 2019 and headquartered in Singapore, specializes in gene therapy. It produces extracellular vesicles from red blood cells as a non-viral, re-dosable gene delivery vehicle, addressing challenges posed by traditional viral-based therapies such as immunogenicity, limited transgene capacity, and manufacturing complexities. The company focuses on developing next-generation gene therapies for hematology, oncology, and immunology.

Destiny Pharma is a clinical-stage biotechnology company based in Brighton, United Kingdom, specializing in the discovery and development of innovative antimicrobial products aimed at treating infectious diseases. The company's lead candidates include XF-73 Nasal, currently in Phase II clinical trials for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, in Phase I trials for treating skin infections caused by antibiotic-resistant bacteria. Destiny Pharma also develops other compounds, such as XF-70 for treating ventilator-associated pneumonia and DPD-207 for eye infections, as well as additional XF drugs targeting antibiotic-resistant biofilm infections. The company has established several collaboration agreements with various academic institutions and organizations, enhancing its research capabilities and broadening its therapeutic focus. Founded in 1996, Destiny Pharma is committed to addressing the growing global healthcare challenge posed by drug-resistant bacteria.

Carbon Biosciences is a biotechnology company focused on developing genetic medicines aimed at treating serious diseases. The company utilizes a proprietary platform based on novel parvoviruses, which have been optimized through natural selection to effectively target specific tissues and deliver larger therapeutic cargoes. This technology is designed to minimize neutralizing immunity, allowing for potential re-dosing. Carbon Biosciences specifically targets lung tissues and has demonstrated success in preclinical models, including those for cystic fibrosis. Through its industrial-scale viral production platforms, the company aims to extend the reach of gene therapies, providing innovative solutions for previously challenging medical conditions.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative therapies using its patented Feldan Shuttle technology. This platform facilitates rapid and secure intracellular delivery of therapeutics, expanding treatment possibilities by accessing previously unreachable cellular components. The company's current pipeline comprises clinical programs leveraging this unique technology to advance novel therapeutic applications.

SalioGen Therapeutics is a biotechnology company focused on developing innovative gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT) platform, the company employs mammal-derived enzymes known as Saliogase to facilitate genome engineering. This approach allows for non-viral delivery of genes of any size, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide safe, durable, and affordable solutions that could transform treatment options for patients with genetic conditions, while also enhancing the efficiency of cell therapy and biologics manufacturing within the healthcare sector.

Peptilogics, Inc. is a clinical-stage biotechnology company based in West Mifflin, Pennsylvania, founded in 2013. The company specializes in designing and developing novel peptide therapeutics aimed at addressing the urgent challenge of multidrug-resistant bacterial infections. Peptilogics utilizes a unique computational platform that enhances drug discovery by exploring new chemical design spaces while ensuring the biological viability and manufacturability of potential therapeutics. Their lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that targets prosthetic joint infections and has received both FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation. Through its innovative eCAP (engineered cationic antibiotic peptide) platform, Peptilogics aims to provide effective treatment options against resistant bacteria and biofilms, ultimately improving patient outcomes and affordability in healthcare.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

EnBiotix, Inc. is a bioengineering company that specializes in developing therapies for chronic and recurrent pulmonary infections, particularly those caused by drug-resistant bacteria. Founded in 2010 and headquartered in Boston, Massachusetts, the company employs innovative platforms, including an anti-persisters platform that enhances antibiotic effectiveness, an engineered bacteriophage platform that targets infections, and a tunable target degradation platform that modifies protein functions. EnBiotix has a diverse clinical pipeline, with notable products such as EBX-001 for P. aeruginosa infections in cystic fibrosis patients, EBX-002 for catheter-associated urinary tract infections, and EPP-001 for prosthetic joint infections. The company's mission is to combat the global rise of antibiotic resistance by revitalizing existing antibiotic classes and addressing a significant market need for effective treatments in the healthcare landscape.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Armata Pharmaceuticals is a clinical-stage biotechnology company headquartered in Marina del Rey, California, specializing in the development of targeted bacteriophage therapeutics for addressing drug-resistant bacterial infections. Founded in 2005, the company aims to combat the rising threat of multidrug-resistant bacteria, which has been exacerbated by antibiotic overuse and poses significant health risks. Armata focuses on creating pathogen-specific bacteriophage therapies, leveraging both natural and synthetic phage candidates to effectively treat infections caused by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. The company is advancing a diverse pipeline of therapeutic candidates and is collaborating with Merck to develop proprietary synthetic phage therapies for specific infectious disease agents.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Microbion Corporation is a biopharmaceutical company based in Bozeman, Montana, dedicated to developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982, the company focuses on bismuth-thiols, which are aimed at treating chronic and acute wound infections, including post-surgical orthopedic infections. Additionally, Microbion works to prevent microbial biofilms from forming on implanted medical devices and to manage these biofilms in various infectious diseases. Its product development includes treatments for moderate to severe diabetic foot ulcers, orthopedic implant-related infections, and military wound-associated infections, targeting both antibiotic-resistant pathogens and chronic wound care. In addition to its operations in Bozeman, Microbion also maintains an office in Vancouver, Canada.

Kinnear Pharmaceuticals is a preclinical stage pharmaceutical company committed to the discovery, development and commercialization of ceragenin-based anti-infective and anti-inflammatory product candidates for diseases with large unmet clinical needs.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

enGene, Inc. is a biotechnology company based in Vancouver, Canada, specializing in mucosal immunotherapy to address inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables the localized delivery of immune-modulating proteins to mucosal tissues, targeting conditions affecting the gastrointestinal tract, lung, and bladder. This innovative platform allows for the systemic release of proteins from the gut, which can be beneficial for treating a variety of immune disorders, as well as other conditions such as diabetes, anemia, and hemophilia. Founded in 1999, enGene has formed a strategic alliance with Takeda Pharmaceutical Company to further advance its therapeutic offerings.

Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Microbion Corporation is a biopharmaceutical company based in Bozeman, Montana, dedicated to developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982, the company focuses on bismuth-thiols, which are aimed at treating chronic and acute wound infections, including post-surgical orthopedic infections. Additionally, Microbion works to prevent microbial biofilms from forming on implanted medical devices and to manage these biofilms in various infectious diseases. Its product development includes treatments for moderate to severe diabetic foot ulcers, orthopedic implant-related infections, and military wound-associated infections, targeting both antibiotic-resistant pathogens and chronic wound care. In addition to its operations in Bozeman, Microbion also maintains an office in Vancouver, Canada.

Crestone is a clinical-stage biopharmaceutical company focused on developing innovative medication candidates for serious bacterial infections. The company's research pipeline includes treatments targeting Clostridioides difficile (C. diff), antibiotic-resistant Gram-positive infections, and tuberculosis. Crestone's platform features several programs designed to address significant unmet medical needs, utilizing novel mechanisms of action to disrupt bacterial growth and resistance, thereby improving treatment outcomes for patients.

Laurent Pharmaceuticals Inc., established in 2012 and based in Montreal, Canada, is a biopharmaceutical company focused on developing orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. Its lead product, LAU-7b, is a novel once-a-day oral form of fenretinide currently in clinical development stages.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

Spirovant Sciences, Inc., established in 2016 and headquartered in Philadelphia, Pennsylvania, specializes in the development of gene therapies for cystic fibrosis and related pulmonary diseases. The company aims to overcome historical barriers in genetic treatments, focusing on adeno-associated viral and lentiviral gene therapy platforms to deliver large payloads, thereby enhancing therapeutic potential. As of late 2019, Spirovant operates as a subsidiary of Sumitovant Biopharma Ltd.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Laurent Pharmaceuticals Inc., established in 2012 and based in Montreal, Canada, is a biopharmaceutical company focused on developing orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. Its lead product, LAU-7b, is a novel once-a-day oral form of fenretinide currently in clinical development stages.

Icagen, Inc. is a biopharmaceutical company based in Durham, North Carolina, specializing in drug discovery with a particular emphasis on neuroscience and rare diseases. Founded in 2003, the company focuses on developing novel orally-administered small molecule drugs that target ion channels, among other therapeutic areas. Icagen provides a range of pre-clinical drug discovery services, including assay development, cell line generation, high-throughput screening, medicinal and computational chemistry, and custom assay services. The company's drug pipeline includes ICA-105665, currently in Phase I trials for epilepsy and neuropathic pain, and Senicapoc, which is undergoing Phase I studies for asthma. Icagen actively collaborates with major pharmaceutical companies, such as Bristol-Myers Squibb, Astellas Pharma, and Pfizer, to advance its research and development initiatives.

Laurent Pharmaceuticals Inc., established in 2012 and based in Montreal, Canada, is a biopharmaceutical company focused on developing orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. Its lead product, LAU-7b, is a novel once-a-day oral form of fenretinide currently in clinical development stages.

Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Sound Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that specializes in developing neurotologic drugs aimed at treating sensorineural diseases of the inner ear. Founded in 2001, the company focuses on creating prescription medications that help prevent and treat hearing loss, specifically targeting sensorineural hearing loss. Sound Pharmaceuticals is working on innovative treatments that involve compounds designed to inhibit growth-inhibitory proteins, allowing non-dividing epithelial cells in the inner ear to divide and potentially transform into replacement auditory hair cells. This approach seeks to address various forms of hearing loss in a cost-effective manner, which represents a significant advancement in auditory health care.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Laurent Pharmaceuticals Inc., established in 2012 and based in Montreal, Canada, is a biopharmaceutical company focused on developing orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. Its lead product, LAU-7b, is a novel once-a-day oral form of fenretinide currently in clinical development stages.

Laurent Pharmaceuticals Inc., established in 2012 and based in Montreal, Canada, is a biopharmaceutical company focused on developing orally-active drug candidates to modulate the immuno-inflammatory response in cystic fibrosis patients. Its lead product, LAU-7b, is a novel once-a-day oral form of fenretinide currently in clinical development stages.

Corbus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, focused on developing and commercializing therapeutics for the treatment of rare and serious inflammatory fibrotic diseases. Founded in 2009, the company’s lead product candidate, lenabasum, is a synthetic, orally administered cannabinoid receptor type 2 (CB2) agonist currently undergoing Phase III clinical trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. Additionally, Corbus is developing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, aimed at treating nonalcoholic steatohepatitis and other fibrotic conditions. The company has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the commercialization of lenabasum in Japan and has a licensing agreement with Jenrin Discovery, LLC to utilize a library of novel compounds targeting the endocannabinoid system. With a commitment to addressing chronic inflammation and fibrotic diseases, Corbus Pharmaceuticals is advancing its pipeline of innovative drug candidates.

Parion Sciences is a development-stage company focused on researching, developing, and commercializing treatments aimed at restoring the innate mucosal surface defenses of patients. These defenses are crucial for maintaining health in areas such as the eyes and lungs, where protective mucus plays a significant role. Parion's innovative technologies specifically target respiratory and ocular diseases that arise when the body's mucosal defense system is compromised due to factors like genetics, aging, or environmental influences. By addressing these unmet medical needs, Parion seeks to enhance the ability of healthcare professionals to effectively restore and protect patients' mucosal surfaces.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Altus Pharmaceuticals is an information technology consulting firm that serves a diverse range of clients, including healthcare providers, manufacturing companies, and financial institutions. The firm positions itself as a strategic partner, providing expertise to help organizations navigate complex challenges and enhance their operational efficiency. With a focus on delivering impactful solutions, Altus aims to support its clients in achieving their goals while addressing the unique demands of their respective industries.